Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BridGene Closes $38.5 Million Funding from China Investors for Novel Small Molecule Targets

publication date: Jul 27, 2022

BridGene Biosciences, a San Jose, CA discovery biotech, completed a $38.5 million Series B funding from China investors led by Lapam Capital, Junson Capital and Dyee Capital. BridGene has developed a proprietary chemoproteomic platform to discover small molecule drug for targets usually considered undruggable. The company’s IMTAC™ platform screens small molecules against the whole proteome or against a prioritized target in live cells to discover drug candidates for diseases that include cancers. The proceeds will also be used to develop BridGene's leading candidate, a covalent TEAD inhibitor, and other oncology projects. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital